Browsing: Comparing

Wellness Tips

GLP-1 Titans Clash: Comparing Eli Lilly and Novo Nordisk

By 0

Novo NordiskNVO and Eli LillyLLY lead the diabetes and obesity market, driven by their blockbuster GLP-1 therapies. Lilly sells its dual GIP/GLP-1 agonist tirzepatide as Mounjaro for type II diabetes and as Zepbound for obesity. Novo Nordisk markets semaglutide as Ozempic and Rybelsus for type II diabetes, and as Wegovy for weight management